The effect of bone marrow-derived mesenchymal stem cell co-transplantation with hematopoietic stem cells on liver fibrosis alleviation and survival in patients with class III β-thalassemia major

Table 3 The 10-year non-relapse mortality (NRM) and rejection rate in the study population

Groups		Rejection rate	P value	Non-relapse mortality (NRM)	P value
Groups		10 years	P value	10 years	P value
Mesenchymal group	Yes	14.46% (7.89–22.93%)	0.88	22.02% (13.69–31.59%)	0.222
Mesenchymal group	No	15.52% (9.87–22.34%)	0.88	31.88% (22.66–41.47%)	0.222
Sex-matched	Mismatched	18.52% (11.66–26.61%)	0.08	31.20% (20.90–42.01%)	0.756
Sex-matched	Matched	10.23% (5.21–17.23%)	0.08	26.74% (18.35–35.85%)	0.756
ABO-mismatched	Mismatched	18.32% (10.78–27.43%)	0.236	30.13% (20.32–40.53%)	0.543
ABO-mismatched	Matched	12.53% (7.48–18.94%)	0.236	27.48% (18.50–37.21%)	0.543
Source of HSCT	PB	13.68% (8.45–20.17%)	0.404	32.12% (23.46–41.09%)	0.109
Source of HSCT	BM	17.39% (10.01–26.46%)	0.404	20.68% (12.32–30.55%)	0.109
Acute GvHD	Yes	15.95% (12.42–21.77%)	0.452	37.47% (28.06–46.85%)	0.256
Acute GvHD	No	22.86% (15.73–30.80%)	0.452	29.31% (21.10–39.21%)	0.256
Chronic GvHD	Yes	16.82% (12.46–25.31%)	0.249	26.77% (16.58–38.02%)	0.349
Chronic GvHD	No	24.32% (17.44–31.83%)	0.249	27.70% (20.27–35.60%)	0.349

TRM transplant-related mortality, GvHD graft-versus-host disease, BM bone marrow, PB peripheral blood

ISSN: 1757-6512